Amy D Shapiro
Overview
Explore the profile of Amy D Shapiro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
1603
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Shapiro A, Nakar C, Parker J, Thibaudeau K, Crea R, Sandset P
Haemophilia
. 2023 Sep;
29(6):1556-1564.
PMID: 37674358
Aim: An open-label phase 2/3 study of plasminogen, human-tvmh administered intravenously in paediatric and adult subjects with type 1 plasminogen deficiency was conducted. Interim data was previously reported. The final...
12.
Dai W, Zhang H, Lund H, Zhang Z, Castleberry M, Rodriguez M, et al.
Science
. 2023 Aug;
381(6661):eadh5207.
PMID: 37651538
Apolipoprotein B (apoB)-lipoproteins initiate and promote atherosclerotic cardiovascular disease. Plasma tissue plasminogen activator (tPA) activity is negatively associated with atherogenic apoB-lipoprotein cholesterol levels in humans, but the mechanisms are unknown....
13.
Gupta S, Shapiro A, Tibesar E
Haemophilia
. 2023 Mar;
29(3):928-930.
PMID: 36944032
No abstract available.
14.
Nugent D, Acharya S, Baumann K, Bedrosian C, Bialas R, Brown K, et al.
Expert Rev Hematol
. 2023 Mar;
16(sup1):55-70.
PMID: 36920862
Background: Ultra-rare inherited bleeding disorders (BDs) present important challenges for generating a strong evidence foundation for optimal diagnosis and management. Without disorder-appropriate treatment, affected individuals potentially face life-threatening bleeding, delayed...
15.
Shapiro A, Hardesty B, Peyvandi F, Iorio A
Res Pract Thromb Haemost
. 2023 Mar;
7(1):100007.
PMID: 36891522
Life expectancy for persons with hemophilia has increased over recent decades due to advances in treatment practice and patient care. Those with hemophilia are now more likely to be affected...
16.
Shapiro A, Kulkarni R, Ragni M, Chambost H, Mahlangu J, Oldenburg J, et al.
Blood Adv
. 2023 Feb;
7(13):3049-3057.
PMID: 36848635
Long-term efficacy and safety of the extended half-life recombinant factor IX Fc fusion protein (rFIXFc) has been established among previously treated patients with severe hemophilia B in 2 phase 3...
17.
Negrier C, Mahlangu J, Lehle M, Chowdary P, Catalani O, Bernardi R, et al.
Lancet Haematol
. 2023 Jan;
10(3):e168-e177.
PMID: 36716761
Background: Clinical trial data are scarce for the use of prophylaxis in people with non-severe haemophilia A. The HAVEN 6 study aims to assess safety and efficacy of emicizumab prophylaxis...
18.
Lewandowska M, Nasr S, Shapiro A
Haemophilia
. 2022 May;
28 Suppl 4:77-92.
PMID: 35521732
Introduction: Recent technological innovations in haemophilia have advanced at an astounding pace, including gene therapy programmes and bioengineered molecules for prophylaxis, products that reduce treatment burden through half-life extension, unique...
19.
Pipe S, Hermans C, Chitlur M, Carcao M, Castaman G, Davis J, et al.
Haemophilia
. 2022 Apr;
28(4):548-556.
PMID: 35475308
Introduction: Eptacog beta is a new recombinant activated human factor VII bypassing agent approved in the United States for the treatment and control of bleeding in patients with haemophilia A...
20.
Caputo R, Shapiro A, Sartori M, Leonardi A, Jeng B, Nakar C, et al.
Ophthalmology
. 2022 Mar;
129(8):955-957.
PMID: 35346720
No abstract available.